Bruno Songel Sanchis | Medicine and Health Sciences | Best Review Paper Award

Bruno Songel Sanchis | Medicine and Health Sciences | Best Review Paper Award

Mr Bruno Songel Sanchis, Hospital clΓ­nico San Carlos, Spain

Mr. Bruno Songel Sanchis πŸŽ»πŸ‘“ is a versatile professional with dual expertise in music and vision sciences. Holding a Master’s in Optometry and Vision Sciences from the Complutense University of Madrid πŸŽ“, and a degree in Optics and Optometry from the University of Valencia, he seamlessly combines clinical acumen with research innovation. His extensive clinical experience spans Hospital ClΓ­nico San Carlos and FundaciΓ³n Salud Visual, focusing on cutting-edge myopia control, glaucoma diagnostics, and AI integration in ophthalmology πŸ€–πŸ§ . Beyond clinics, Bruno’s passion for community service is evident through his impactful volunteer roles and outreach projects 🫢. A talented cellist 🎢 and a committed scientist, he bridges the gap between art and science with grace and dedication. His systematic review on ocular manifestations in IBD showcases his research depth πŸ“„πŸ“Š. A creative thinker and empathetic clinician, Bruno is a promising contender for the Best Review Paper Award πŸ₯‡πŸ§¬.

Publication Profile

Orcid

Education

Bruno Songel Sanchis has a rich and interdisciplinary educational background πŸŽ“βœ¨. He earned his Professional Degree in Music (Violoncello) from the Professional Music Conservatory of Valencia 🎻, showcasing his artistic talents. He later pursued a Scientific Baccalaureate at San JosΓ© de Calasanz High School πŸ§ͺπŸ“˜. Bruno’s scientific journey led him to the University of Valencia, where he obtained his Degree in Optics and Optometry πŸ‘οΈπŸ“. Committed to advancing vision care, he continued with a Master’s Degree in Optometry and Vision Sciences at the prestigious Complutense University of Madrid πŸ‘“πŸ”¬. He’s currently engaged in Project Efficiency Boost (2025–present), enhancing clinical productivity through AI and innovation πŸš€πŸ€–. His academic versatility reflects both analytical rigor and creativity, a rare blend that empowers his impactful work in clinical practice and scientific research πŸ§ πŸ“š.

Experience

Bruno has extensive hands-on experience in both clinical and research settings πŸ₯πŸ”¬. He served as a Clinical Optometrist at Hospital ClΓ­nico San Carlos (Madrid), rotating across subspecialties like myopia, retina, glaucoma, and cataracts πŸ‘οΈπŸ’‰. He contributed to pivotal research on myopia control with Atropine and later as a Clinical Research Technician at IdISSC, focused on the β€˜LYDIA project’ developing AI diagnostic tools πŸ€–πŸ“Š. His role as a Product Specialist marked a major milestoneβ€”implementing Europe’s first AI-powered ophthalmic imaging system at La Paz Hospital πŸ₯✨. Earlier, he worked at Γ“ptica Universitaria and Alain Afflelou, gaining practical skills in optometry, sales, and customer care πŸ› οΈπŸ›οΈ. Bruno also holds a current role at FundaciΓ³n Salud Visual (Funsavi), continuing his clinical contributions while mentoring others. These experiences shape him into a well-rounded professional with deep clinical knowledge, technical skills, and patient-centered care focus πŸ‘“πŸ«Ά.

Awards and Honors

Bruno Songel Sanchis has garnered multiple honors for both creativity and scientific excellence πŸ†πŸ“š. He won 1st prize in the UV Creative Outreach Project (2021) for innovative public science engagement πŸŽ¨πŸ’‘. At the UVemprΓ©n Startup – Crea Awards, he secured 3rd position for his entrepreneurial vision in healthcare πŸ”¬πŸš€. His musical talents earned him an Honorable Mention Diploma at an International Music Seminar, reflecting his multifaceted abilities πŸŽΆπŸ…. He was also a Finalist in the MOTIVEM UV Awards, acknowledging his academic initiative and leadership πŸ“˜πŸ‘. As a Rapporteur at the SIYO 2022 Congress for Young Optometrists, he showcased his ability to bridge science and communication πŸ—£οΈπŸ“Š. His certifications from the London School of Hygiene and Tropical Medicine in public health ophthalmology further validate his global competence in preventing blindness and tackling ocular diseases on an international level πŸŒπŸ‘οΈ.

Research Focus

Bruno Songel Sanchis’s research focuses on clinical optometry, ocular disease prevention, and artificial intelligence applications in ophthalmology πŸ§ πŸ‘οΈπŸ€–. His major interests include myopia control, particularly using Atropine-based treatments, and early detection of age-related macular degeneration and glaucoma through AI-powered diagnostic systems πŸ§¬πŸ“ˆ. In collaboration with top-tier hospitals and research institutions, Bruno played a pivotal role in developing multi-diagnostic tools and conducting clinical trials on visual pathologies. His review on ocular extraintestinal manifestations in inflammatory bowel disease (IBD) offers critical insights into interdisciplinary patient care πŸ“„πŸ©Ί. A blend of practical clinical work and technical innovation defines his approach, with the goal of improving accessibility and effectiveness of vision care globally 🌐✨. His ongoing contributions to AI integration, coupled with community eye health initiatives, make him a forward-thinking optometrist and researcher committed to impactful, data-driven healthcare advancements πŸ©»πŸ“Š.

Publication Top Notes

Analysis of the Incidence of Ocular Extraintestinal Manifestations in Inflammatory Bowel Disease Patients: A Systematic Review (2024)

 

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States

Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.

Publication Profile

Scopus

Education

Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.

Experience

Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.

Awards and Honors

Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year πŸ† (Miller School of Medicine, 2015), the Outstanding Care Award πŸ… (Sarcoma Alliance, 2012), and the Leadership in Clinical Research πŸŽ–οΈ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.

Research Focus

Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.

Publication Top Notes

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours

Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER